Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.
暂无分享,去创建一个
M. Ladanyi | A. Drilon | C. Rudin | M. Kris | G. Ganji | M. Arcila | Gregory Riely | R. Somwar | N. Rekhtman | W. Lockwood | R. Benayed | H. Edgren | K. Ng | Roger S Smith | V. Martinez | A. Ruusulehto | A. Plodkowski | C. Matheny | J. Montecalvo | Victor D. Martinez | P. Desmeules | J. Sabari | M. Vojnic | Huichun Tai | Jason C. Chang | L. Delasos | Biju Mangatt
[1] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[2] A. Rossi,et al. Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression , 2017, Oncotarget.
[3] E. Pleasance,et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Tsao,et al. A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] A. Drilon,et al. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.
[6] C. Corless,et al. Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] J. Barret,et al. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3 , 2017, Molecular Cancer Therapeutics.
[8] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[9] M. Antoine,et al. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma , 2016, Cancer medicine.
[10] H. You,et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung , 2016, Oncotarget.
[11] S. Sugano,et al. Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit. , 2016, Cancer research.
[12] S. Sleijfer,et al. First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors , 2015, Clinical Cancer Research.
[13] Maristela L Onozato,et al. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[15] Richard Nicoletti,et al. Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models , 2014, Clinical Cancer Research.
[16] Roman K. Thomas,et al. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer , 2014, Clinical Cancer Research.
[17] C. Matheny,et al. 300 Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3 , 2014 .
[18] Koji Tsuta,et al. Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma , 2014, Clinical Cancer Research.
[19] I. Petersen,et al. CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.
[20] Jianxiang Wang,et al. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells , 2013, Molecular Cancer.
[21] M. Sliwkowski,et al. Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy , 2013, Clinical Cancer Research.
[22] W. Sellers,et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. , 2013, Cancer research.
[23] P. Edwards,et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene , 2003, Genes, chromosomes & cancer.
[24] K. L. Pierce,et al. Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.
[25] M. Sliwkowski,et al. γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175 , 1997, Oncogene.